EU Framework Reforms and their Impact
Ireland’s stance on new EU pharmaceutical regulations is still developing, according to the Department of Health. These regulations aim to update the EU’s 20-year-old pharmaceutical framework to make medicines more accessible and affordable, and to strengthen supply chains to prevent further shortages. They also introduce stricter environmental policies for drug development.
The proposals were introduced in early 2023 but have moved slowly through the European Parliament. Major pharmaceutical companies argue that the new rules could discourage research and development (R&D) investments in Europe.
A key issue is how long companies should notify authorities about upcoming supply disruptions. Teva Pharmaceuticals, with a large base in Waterford, supports a three-month notice period but warns against extending it to six months, which they say could create unnecessary regulatory burdens and false alarms.
Health Minister Stephen Donnelly set up a working group in 2023 to handle Ireland’s evolving stance on the legislation. Ireland supports a coordinated EU approach to prevent medicine shortages and ensure strong supply chains but has not taken a specific position on the notification periods.
Innovation & Competitiveness
According to a survey conducted in June by the research firm Global Data, companies have varied opinions on the reforms. Specifically, 47% of industry respondents were neutral, 32% were positive, and 21% were negative about the changes. Companies like Teva, Astellas, Pfizer, and AstraZeneca have raised concerns, especially about how the reforms might affect innovation, competitiveness, and the protection of regulatory data.
Overall, while the legislation aims to benefit public health and the environment, pharmaceutical companies are concerned about the potential negative impacts on their operations, innovation, and competitiveness.